The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 93 results:
Author [ Title(Desc)] Type Year
Filters: Author is Anastasilakis, Athanasios D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Pavlidou V., Koukoulis G., et al. (2008).  Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.. Eur J Endocrinol. 158(3), 411-5.
Anastasilakis, A. D., Polyzos S. A., Makras P., Sakellariou G. T., Bisbinas I., Gkiomisi A., et al. (2012).  Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.. Bone. 50(5), 1130-4.
Polyzos, S. A., Anastasilakis A. D., & Arsos G. (2012).  Acute transient thyroid swelling following needle biopsy: an update.. Hormones (Athens). 11(2), 147-50.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review.. Thyroid. 20(3), 265-71.
Kourtis, A., Gkiomisi A., Mouzaki M., Makedou K., Anastasilakis A. D., Toulis K. A., et al. (2011).  Apelin levels in normal pregnancy.. Clin Endocrinol (Oxf). 75(3), 367-71.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Anastasilakis, D. A., Makras P., Polyzos S. A., & Anastasilakis A. D. (2019).  Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview.. Hormones (Athens). 18(1), 65-70.
B
Anastasilakis, A. D., Tsourdi E., Makras P., Polyzos S. A., Meier C., McCloskey E. V., et al. (2019).  Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.. Bone. 127, 401-418.
C
Anastasilakis, A. D., Polyzos S. A., Skouvaklidou E. C., Kynigopoulos G., Saridakis Z. G., Apostolou A., et al. (2016).  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.. Metabolism. 65(10), 1459-65.
Anastasilakis, A. D., Polyzos S. A., Saridakis Z. G., Kynigopoulos G., Skouvaklidou E. C., Molyvas D., et al. (2014).  Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition.. J Clin Endocrinol Metab. 99(9), 3247-55.
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Anastasilakis, A. D., Polyzos S. A., Makras P., Rauner M., Sonnleitner L., Hawa G., et al. (2019).  Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.. J Musculoskelet Neuronal Interact. 19(3), 253-257.
Sakellariou, G. T., Anastasilakis A. D., Bisbinas I., Oikonomou D., Gerou S., Polyzos S. A., et al. (2015).  Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.. Rheumatology (Oxford). 54(5), 908-14.
Polyzos, S. A., Anastasilakis A. D., Kountouras J., Makras P., Papatheodorou A., Kokkoris P., et al. (2016).  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.. J Bone Miner Metab. 34(4), 447-56.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Polyzos, S. A., & Anastasilakis A. D. (2009).  Clinical complications following thyroid fine-needle biopsy: a systematic review.. Clin Endocrinol (Oxf). 71(2), 157-65.
Anastasilakis, A. D., Polyzos S. A., Makras P., Aubry-Rozier B., Kaouri S., & Lamy O. (2017).  Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.. J Bone Miner Res. 32(6), 1291-1296.
Anastasilakis, A. D., Ruggeri R-M., Polyzos S. A., Makras P., Molyva D., Campennì A., et al. (2013).  Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.. Metabolism. 62(10), 1350-6.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., & Makras P. (2020).  Combination and sequential treatment in women with postmenopausal osteoporosis.. Expert Opin Pharmacother. 21(4), 477-490.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.